According to recent research from the U.S. Centers for Disease Control and Prevention, the trend in indoor tanning among high school students is on the decline. However, white females remain the demographic with the highest incidence of use.
MRV Research
SolaranRx to Present Melanoma-Fighting Technology at San Francisco’s Biotech Showcase
SolaranRx, Inc., which is developing a peptide-based technology for treating metastatic melanoma, is among the featured presenters at Biotech Showcase™, January 12-14 in San Francisco. SolaranRx’s lead product, SRX-1177, was recently selected among the 2014 Top 10 Most Interesting Oncology Projects to Watch by Informa and Kantar Health for its strong science and potential to address unmet medical needs in treating metastatic melanoma.
Study of Castle Biosciences’ Skin Melanoma Gene Test Published in Clinical Cancer Research
Castle Biosciences Inc. today announced the publication of a clinical validation study of its gene expression profile (GEP) test for cutaneous melanoma. DecisionDx-Melanoma accurately predicts metastatic risk independent of current diagnostic modalities including AJCC staging. The paper “Development of a Prognostic Genetic Signature to Predict the Metastatic Risk Associated with Cutaneous Melanoma” was published today in Clinical Cancer Research a publication of the American Association for Cancer Research (AACR).
MSK Plays Critical Role in FDA Approval of New Melanoma Drug
On December 22, the US Food and Drug Administration approved a new treatment for people with melanoma that cannot be surgically removed or has metastasized, or spread, and no longer responds to other therapies. After the drug, nivolumab (Opdivo™), was shown to shrink tumors in a clinical trial, it received accelerated approval, which allows patients earlier access to promising therapies that show effectiveness during a study.